Tobira Therapeutics Inc. (NASDAQ:TBRA) reached a new 52-week low on Tuesday . The company traded as low as $4.14 and last traded at $4.26, with a volume of 606,419 shares trading hands. The stock had previously closed at $4.50.

TBRA has been the subject of a number of recent analyst reports. Zacks Investment Research cut Tobira Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Cantor Fitzgerald initiated coverage on Tobira Therapeutics in a report on Wednesday, July 6th. They set a “buy” rating and a $27.00 price target for the company. Cowen and Company reaffirmed a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $18.00 price target on shares of Tobira Therapeutics in a report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Tobira Therapeutics has an average rating of “Buy” and an average price target of $18.60.

The firm has a 50-day moving average of $11.18 and a 200-day moving average of $8.68. The firm’s market cap is $79.78 million.

Tobira Therapeutics (NASDAQ:TBRA) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.12. Equities research analysts predict that Tobira Therapeutics Inc. will post ($2.49) EPS for the current year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 59,067 shares of the company’s stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total transaction of $709,985.34. Following the completion of the sale, the insider now directly owns 1,914,541 shares in the company, valued at $23,012,782.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP purchased a new stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned about 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.